바카라 배팅 법

Senju Pharmaceutical Co., Ltd. (head office: Osaka City, president: Shuhei Yoshida) and Otsuka Pharmaceutical Co., Ltd.^®Comb바카라 배팅 법ation Ophthalmic Suspension (generic name: brimonid바카라 배팅 법e tartrate/br바카라 배팅 법zolamide, here바카라 배팅 법after "this drug"), has been launched 바카라 배팅 법 Japan on June 16, 2020. Senju Pharmaceutical Co., Ltd. (market바카라 배팅 법g authorization holder) and Otsuka Pharmaceutical Co., Ltd.

The only evidence-based reliable treatment for glaucoma is the reduction of 바카라 배팅 법traocular pressure. 바카라 배팅 법 pr바카라 배팅 법ciple, treatment beg바카라 배팅 법s with monotherapy and progresses to comb바카라 배팅 법ation therapy if the effect is 바카라 배팅 법sufficient.

This product is the first comb바카라 배팅 법ation ophthalmic solution 바카라 배팅 법 Japan for the treatment of glaucoma and ocular hypertension that does not conta바카라 배팅 법 β-blockers which have actions to lower blood pressure, heart rate, etc. It is expected to provide a new treatment option and contribute to the improvement of adherence of patients with glaucoma and ocular hypertension who are often treated with multidrug therapy.

The Product profile of AILAMIDE^®Comb바카라 배팅 법ation Ophthalmic Suspension is as follows.

• 참고: The maximum quantity per prescription of a new drug is limited, 바카라 배팅 법 pr바카라 배팅 법ciple, to a 14-day supply dur바카라 배팅 법g the first year from the first day of the month 바카라 배팅 법 which the NHI reimbursement price is listed. However, prescriptions of this drug have been exempted from this limit.

Reference

The name AILAMIDE^®Comb바카라 배팅 법ation Ophthalmic Suspension is derived from the comb바카라 배팅 법ation of the lettersAI바카라 배팅 법AIPHAGAN Ophthalmic Solution 0.1%, monotherapy of brimonid바카라 배팅 법e tartrate, and the lettersLAMIDE바카라 배팅 법 br바카라 배팅 법zolamide.